MVIR
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Medivir develops drugs with a focus on cancer diseases where the medical needs are great. The drug candidates are directed towards indication areas where available treatment methods are limited or absent. Medivir focuses on the development of fostrox, a drug candidate that has been designed to selectively treat cancer cells in the liver. The company was founded in 1988 and is headquartered in Huddinge.
Read moreInterim report Q2'26
Interim report Q3'26
Revenue M
EBIT-% (adj.)
EPS (adj.)
Dividend %
Don't miss out - create an account and get all the possible benefits